Search

Your search keyword '"Kelley, Robin K."' showing total 442 results

Search Constraints

Start Over You searched for: Author "Kelley, Robin K." Remove constraint Author: "Kelley, Robin K."
442 results on '"Kelley, Robin K."'

Search Results

1. Polyunsaturated fatty acid-bound alpha-fetoprotein promotes immune suppression by altering human dendritic cell metabolism

2. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis

4. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

5. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

7. Discovering dominant tumor immune archetypes in a pan-cancer census

8. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

9. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma

11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

12. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

13. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019

14. Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma

15. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

16. Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

17. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation

18. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

20. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

21. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

22. An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

23. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

25. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma—a real-world, multicenter study.

26. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.

28. Hybrid Capture‐Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1‐Mutant Cholangiocarcinoma Harboring a Novel YWHAZ‐BRAF Fusion

29. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

30. Cholangiocarcinoma — evolving concepts and therapeutic strategies

31. Evidence and Choice: The BCLC Vision for Tailoring Clinical Decision-Making

32. Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study

33. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls

34. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas

35. Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

37. Genomic sequencing: assessing the health care system, policy, and big-data implications.

38. Corrigendum to “EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma” [J Hepatol (79) (2023) 181–208]

39. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma

40. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

41. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

42. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

43. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

44. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

45. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

46. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

47. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

48. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

49. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

50. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

Catalog

Books, media, physical & digital resources